N/A
N=32
Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis
Arterial Hypertension · Hemodialysis
Bottom Line
View on ClinicalTrials.gov: NCT06764277 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Cardiac Output — 3.9; 4.10; 4.6 L/min
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- There will be no intervention (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Bernardo Rodríguez Iturbe
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cardiac Output |
3.9; 4.10; 4.6 | — |
| PRIMARY Interdialytic Weight Change |
2.90; 3.22; 2.98 | — |
| PRIMARY Systemic Vascular Resistance |
1513; 2045; 1751 | — |
| SECONDARY Angiotensin II Serum Levels |
105.3; 158.3; 231.5 | — |
| SECONDARY Monocyte+Neutrophiles/Lymphocyte Ratio (MNLR) |
0.88; 0.73; 1.11 | — |
| SECONDARY Serum Norepinephrine Levels |
81.4; 82.4; 82.6 | — |
| SECONDARY Serum Copeptin Levels |
14.6; 10.3; 13.0 | — |
| SECONDARY Hypertension Phenotypes |
8; 1; 13; 10 | — |
Summary
The goal of this study is to evaluate interdialytic blood pressure changes of the patients in chronic hemodialysis.
The main question to be answered is: What is the relative importance of weight gain, the renin angiotensin system, the sympathetic nervous system and inflammatory immune reactivity in the interdialytic hypertension of patients in chronic hemodialysis, The participants will have hemodynamic evaluation (cardiac output and peripheral vascular resistance) at the end of dialysis, ambulatory monitoring of blood pressure in the interdialytic period. Serum samples will be collected at the end of dialysis and before the start of the next dialysis, 2-3 days later.
Eligibility Criteria
Inclusion Criteria
- Patients with more than 3 months in the chronic hemodialysis program in the INCMNSZ and assumed to remained in the program for longer than 3 months
- Stable patients with no change in medication 1 month prior to the study
- Unchanged drug therapy and dialysis prescription for >1 month prior to the studies
- Informed consent to participate in the study
Exclusion Criteria
- Patients unable to give informed consent or withdrawal of informed consent to the study
- Patients with active infection
- Patients with prosthesis or pacemakers
- Patients with immunosuppressive treatment of more than 10mg Prednisone daily
- Prior nephrectomy
- incomplete collection of data specified in the study protocol
Data sourced from ClinicalTrials.gov (NCT06764277). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.